ClinicalTrials.gg
Not yet recruitingNCT07225140Updated Nov 19, 2026

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

A Phase 3 interventional study of Combogesic® tablets and Acetaminophen 500mg in Post Operative Pain, Acute, sponsored by AFT Pharmaceuticals, Ltd.. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
185th of 1,099
180 · median 76
Started
2027
with 11 others
Phase 3
162 of 1,181
18 open now
Primary completion
2027-10
later than 170 of 236 live
Registered
1,115th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 185th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 12 that started in 2027, is one of 162 in phase 3, reaches primary completion later than 170 of the 236 other live ones, and was the 1,115th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

Combogesic® 325 contains a combination of ibuprofen and acetaminophen. The purpose of this study is to compare the pain relief effects of Combogesic® 325mg and acetaminophen and to evaluate the safety of Combogesic® 325mg in adolescents between the ages of 12 and \<18 years.

What will the study involve for participants?

  • Participants will be randomly allocated to one of 3 treatment groups:

    • 3 tablets of Combogesic® 325,
    • 2 tablets of Combogesic® 325 and 1 tablet of placebo or
    • 2 tablets of acetaminophen1000mg and 1 tablet of placebo
  • Participants will take 3 tablets every 6 hours with a maximum of 4 doses in 24 hours
  • Participants and study doctor will be blinded to the treatment group
  • If pain is not sufficiently controlled, opioids may be used as supplementary pain relief at the discretion of the study doctor.
  • Participants will complete a patient diary to assess their pain
  • Participants will rate the study drug at the end of the treatment.

It is expected that Combogesic® tablets (either 2 or 3 tablets per dose) will provide a greater reduction in pain compared to acetaminophen (1000 mg) treatment.

03

Conditions studied

  • Post Operative Pain, Acute

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written or consent be provided from parents/legal guardians and assent from participants (where appropriate).
  • Be males and females aged at least 12 years and less than 18 years old on both the day of consent and throughout the 24 hour study period.
  • Be undergoing planned orthopedic surgery which requires at least 24 hours of hospital inpatient stay.
  • Have a clinical indication of acute moderate or severe pain (at least ≥ 50 mm on the VAS scale*) within 6 hours after the completion of surgery associated with orthopedic surgery.
  • using a 100mm VAS scale with 0 = no pain and 100 = worst pain imaginable, patients should have a resting VAS pain intensity score of ≥ 50 mm for inclusion. For this study, moderate pain is defined as ≥ 40 mm to ≤ 69 mm and severe pain is defined as a resting VAS of ≥ 70 mm to ≤ 100 mm.
  • Have negative and \& C test results.

Exclusion criteria

Exclusion Criteria:

  • Has taken any NSAID or acetaminophen containing drug products within 5 half-lives prior to the initial dose of study drug.
  • to opioids, NSAIDs or acetaminophen or a history of severe/serious drug reaction to NSAIDs or acetaminophen.
  • Pregnant or lactating females Known to be pregnant or possibly pregnant.
  • Sexually active females of not using adequate * and sexually active males not using adequate contraception**
  • Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence (should the participant become sexually active, she must agree to use a double-barrier method of contraception). A woman of childbearing potential is defined as any female who is less than 2 years or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy.
  • Women of childbearing potential who are unwilling to undergo a urine pregnancy test.
  • Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the Investigator, makes the participant unsuitable from an efficacy or safety perspective.
  • In the opinion of the Investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
  • Currently or in last 30 days, has been in a clinical trial involving another study drug.
  • Have donated blood or blood products within 30 days prior to study drug administration
  • Advanced renal impairment (serum creatinine >132 µmol/L) or a risk for renal failure due to volume depletion.
  • Severe known haemopoietic, renal or hepatic disease, or , including any finding from the laboratory tests results (biochemistry and hematology at screening), which, in the opinion of the Investigator, means that it would not be in the participants' best interests to participate in this study.
  • History of gastric ulceration or other GI disorders that, in the opinion of the Investigator make the participant unsuitable (e.g. frequent treatment of gastroesophageal reflux disease, inflammatory bowel disease, etc).
  • History of severe asthma in the opinion of the investigator.
  • Has a history of drug or alcohol abuse
  • Suffering from any other disease or condition which, in the opinion of the Investigator, means that it would not be in the participant's best interests to participate in this study.

    • Methods of contraception that are deemed adequate have failure rates of \< 1%, including: established use of oral contraceptives in conjunction with a barrier method of contraception; injected or implanted hormonal methods of contraception; placement of intrauterine device (IUD) or intrauterine system (IUS); sexual abstinence; hysterectomy; post-menopausal; sterilized; vasectomy. Suitable contraception should be used for the entire study period, from screening to follow-up. Women of childbearing age include all women that have begun puberty and had their first menstrual period until they reach menopause.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Treatment A- 3 tablets of Combogesic® tablets

    3 tablets of Combogesic® (acetaminophen 975mg + ibuprofen 292.5 mg, total per dose) will be administered every 6 hours up to a maximum of 4 doses in 24 hours.

    Drug: Combogesic® tablets

  • Experimental
    Treatment B- 2 tablets of Combogesic® + 1 tablets of placebo

    2 tablets of Combogesic® (acetaminophen 650 mg + ibuprofen 195 mg, total per dose) and 1 tablet of placebo will be administered every 6 hours up to a maximum of 4 doses in 24 hours.

    Drug: Combogesic® tablets · Drug: Placebo

  • Active comparator
    Treatment C - 2 tablets of acetaminophen and 1 tablet of placebo

    2 tablets of acetaminophen (1000 mg total per dose) + 1 tablet of placebo will be administered every 6 hours up to a maximum of 4 doses in 24 hours.

    Drug: Acetaminophen 500mg · Drug: Placebo

Interventions

  • DrugCombogesic® tablets

    The active ingredients of Combogesic® tablets are acetaminophen 325 mg and ibuprofen 97.5 mg.

    Also known as: Acetaminophen 325 mg and ibuprofen 97.5 mg

  • DrugAcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each tablet contains acetaminophen 500mg.

  • DrugPlacebo

    Placebo tablets do not contain any active ingredients

06

What researchers measure

Primary outcomes

  1. Time-adjusted summed pain intensity difference (SPID) calculated from the visual analogue scale (VAS) pain intensity scores 6 hours after first dose of study medication

    SPID will be derived from the 100 mm Visual Analogue Scale which is the tool used for patients to rate the intensity of their pain on a horizontal 100mm line with 0 on one end and 100 on the other end (0 being no pain and 100 being the worst pain unimaginable). The primary analysis will compare three tablets of Combogesic® against acetaminophen

    Time frame: From start of exposure to study drug until 6 hours after first dose

Secondary outcomes

  1. Time-adjusted SPID0-6 (for 2 tablets of Combogesic vs. acetaminophen) and Time-adjusted SPID0-12, SPID0-18 and SPID0-24 for both doses.

    Time frame: From start of exposure to study medication up to 24 hours

  2. The time to onset of pain relief after the first dose of study drug defined as (i) perceptible, (ii) meaningful and (iii) complete pain relief using the three stopwatch method.

    Time frame: From start of exposure to study medication up to 24 hours

  3. The maximum VAS pain scores up to 24 hours after the first dose of study medication.

    100 mm Visual Analogue Scale is the tool used for patients to rate the intensity of their pain on a horizontal 100mm line with 0 on one end and 100 on the other end (0 being no pain and 100 being the worst pain unimaginable)

    Time frame: From start of exposure to study medication up to 24 hours

  4. The pain intensity (PI) and pain intensity difference (PID) at 6, 12, 18, and 24 hours after first dose.

    100 mm Visual Analogue Scale which is the tool used for patients to rate the intensity of their pain on a horizontal 100mm line with 0 on one end and 100 on the other end (0 being no pain and 100 being the worst pain unimaginable). The PID will be measured by the difference between the baseline score and the score at 6, 12, 18, and 24 hours after first dose.

    Time frame: From start of exposure to study medication up to 24 hours

  5. Pain relief as measured on a 5-point categorical scale at 6, 12, 18, and 24 hours after first dose.

    Patients will be asked to rate their pain in their patient diary with the following questionnaire. Please rate your pain relief: 0= no pain relief; (the pain is the same, or worse, than the starting pain) 1. a little pain relief; (the pain is less than half gone) 2. some pain relief; (the pain is about half gone) 3. a lot of pain relief; (the pain is more than half gone) 4. complete pain relief; (the pain is completely gone)

    Time frame: From start of exposure to study medication up to 24 hours

  6. Peak pain relief

    Time frame: From start of exposure to study medication up to 24 hours

  7. Time to peak pain relief

    Time frame: From start of exposure to study medication up to 24 hours

  8. Total pain relief (TOTPAR) (calculated as a time-weighted average) over 0-6 hours (TOTPAR-6), over 0-12 hours (TOTPAR-12), over 0-18 hours (TOTPAR-18), and over 0-24 hours (TOTPAR-24).

    Time frame: From start of exposure to study medication up to 24 hours

  9. The response rates (response rate to be defined as the percentage of participants who reduce their pain intensity scores by at least 50% compared with the baseline VAS measure).

    Time frame: From start of exposure to study medication up to 24 hours

  10. Time to response

    Time frame: From start of exposure to study medication up to 24 hours

  11. The time to requirement for rescue medication.

    Time frame: From start of exposure to study medication up to 24 hours

  12. The percentage of participants using rescue medication at 6, 12, 18, and 24 hours after first dose.

    Time frame: From start of exposure to study medication up to 24 hours

  13. Total Dose (mg) of primary (oxycodone) and secondary (morphine) rescue medication over 24 hours

    Time frame: From start of exposure to study medication up to 24 hours

  14. Total oral Morphine Milligram Equivalent (MME) dose of all rescue medication over the 24 hour study period

    Time frame: From start of exposure to study medication up to 24 hours

  15. The categorical global evaluation of study drug.

    Each patient will rate the study medication using a questionnaire of: How do you rate the study medication? 1 = Poor; 2 = Fair; 3 = Good; 4 = Very Good; 5 = Excellent The patient's global evaluation of the study drug will be summarized by the number and percentage of subjects within each category.

    Time frame: From start of exposure to study medication up to 24 hours

  16. To compare treatment-emergent adverse event (TEAE) rates over the course of treatment and at a follow up call 7 days after last dose.

    Time frame: From start of exposure to study medication until 7 days after last dose

  17. The incidence of specific NSAID and acetaminophen adverse effects from the first dose of study drug until Day 7.

    Adverse effects include GI ulceration or bleeding, indigestion/stomach pain, post-operative bleeding, bronchospasm, skin reactions, water retention, renal failure, thromboembolic events, and evidence of clinical hepatitis

    Time frame: From start of exposure to study medication until 7 days after final dose

  18. To characterize the pharmacokinetic profile of two different doses of Combogesic® 325 (T1/2- Time required for the plasma drug concentration to decrease by one half)

    This will be defined from the plasma concentration versus time data using non-compartmental methods

    Time frame: Approximately 15 minutes before first dose of study medication until 6 hours after first study medication administration and before second dose

  19. To characterize the pharmacokinetic profile of two different doses of Combogesic® 325 (Extrapolated AUC(0-∞)- The area under the plasma concentration versus time curve, from zero to infinity)

    This will be defined from the plasma concentration versus time data using non-compartmental methods

    Time frame: Approximately 15 minutes before first dose of study medication until 6 hours after first study medication administration and before second dose

  20. To characterize the pharmacokinetic profile of two different doses of Combogesic® 325 (Cmax- Maximum measured plasma concentration)

    This will be defined from the plasma concentration versus time data using non-compartmental methods

    Time frame: Approximately 15 minutes before first dose of study medication until 6 hours after first study medication administration and before second dose

  21. To characterize the pharmacokinetic profile of two different doses of Combogesic® 325 (Tmax- Time to maximum measured plasma concentration)

    This will be defined from the plasma concentration versus time data using non-compartmental methods

    Time frame: Approximately 15 minutes before first dose of study medication until 6 hours after first study medication administration and before second dose

  22. To characterize the pharmacokinetic profile of two different doses of Combogesic® 325 (AUC(0-t) - The area under the plasma concentration versus time curve from time zero to the last measurable concentration)

    This will be defined from the plasma concentration versus time data using non-compartmental methods

    Time frame: Approximately 15 minutes before first dose of study medication until 6 hours after first study medication administration and before second dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 9 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Nov 5, 2025
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Oct 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07225140
Lead sponsor
AFT Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Nov 5, 2025
Start date
Jan 2027 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Laura Boddington
Contact
laura.boddington@aftpharm.com
+64 9 488 0232 ext 735

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion